X4 Pharmaceuticals (XFOR) Net Cash Flow (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Net Cash Flow for 10 consecutive years, with -$21.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 1776.08% year-over-year to -$21.7 million; the trailing twelve-month figure through Jun 2026 stood at $155.8 million (up 244.08% YoY), and the FY2025 full-year result was $161.2 million, up 469.5% from the prior year.
• Net Cash Flow fell to -$21.7 million in Q2 2026 per XFOR's latest filing, from -$346000.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $147.4 million in Q4 2025 and bottomed at -$52.8 million in Q3 2023.
• Historically, Net Cash Flow has averaged $252888.9 across 5 years, with a median of -$15.4 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Net Cash Flow jumped 654.31% in 2022, then plunged 1776.08% in 2026.
• Over 5 years, Net Cash Flow stood at $41.5 million in 2022, then plunged by 178.24% to -$32.5 million in 2023, then retreated by 27.7% to -$41.5 million in 2024, then jumped by 455.4% to $147.4 million in 2025, then sank by 114.74% to -$21.7 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$21.7 million, -$346000.0, and $147.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.